Revolution Medicines, Inc.
RVMDNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $11.6M | $35.4M | $29.4M | $11.5M |
| Operating income | −$1.18B | −$689.5M | −$487.2M | −$258.3M | −$188.0M | −$110.7M |
| Net income | −$1.13B | −$600.1M | −$436.4M | −$248.7M | −$187.1M | −$19.5M |
| Total assets | $2.35B | $2.56B | $2.06B | $811.9M | $738.0M | $567.4M |
| Total liabilities | $723.2M | $293.1M | $235.5M | $126.7M | $135.4M | $92.7M |
| Equity | $1.63B | $2.27B | $1.83B | $685.2M | $602.6M | $474.7M |
| EPS (diluted) | $-5.95 | $-3.58 | $-3.86 | $-3.08 | $-2.57 | $-2.01 |
| Shares out. | 185.9M | 164.7M | 90.5M | 74.2M | 73.4M | 66.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −69.3%
- Return on assets
- −48.0%
- Return on capital (ROCE)
- −57.3%
- Liabilities / assets
- 30.7%
- Debt / equity
- 0.44×
- Book value / share
- $8.77
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -0.01distress
- Accruals / assets
- −9.9%clean
- Piotroski F-Score
- 1/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2026-04-30Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Phase 3Active Not Recruitingreadout ~2026-06Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- Phase 1Active Not Recruitingreadout ~2027-03-31Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
- Phase 1/2Recruitingreadout ~2027-05-15Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Phase 1/2Recruitingreadout ~2027-05-31Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Phase 1/2Recruitingreadout ~2027-06Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Phase 3Recruitingreadout ~2027-12-01Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Phase 1Recruitingreadout ~2028-04Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Janus Henderson Group PlcPassive (13G)May 15, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Baker Bros. Advisors LpPassive (13G)Feb 17, 2026
- Wellington Management Group LlpPassive (13G)Feb 10, 2026
- Farallon Capital Partners, L.P.Passive (13G)Feb 9, 2026
- Fmr LlcPassive (13G)Nov 5, 2025
- Blackrock, Inc.Passive (13G)Jul 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 11.1M | 4.7 | -13.5% |
| Apr 30, 2026 | 12.8M | 3.3 | -4.4% |
| Apr 15, 2026 | 13.4M | 3.0 | -13.1% |
| Mar 31, 2026 | 15.4M | 7.9 | +6.6% |
| Mar 13, 2026 | 14.5M | 7.8 | +2.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 6, 2026
- Entered a material agreement · New financial obligation · Other material eventApr 17, 2026
- Other material eventApr 16, 2026
- Other material eventApr 13, 2026
- Results of operationsFeb 25, 2026
- Results of operationsNov 5, 2025
- Other material eventOct 17, 2025
- Other material eventSep 10, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.